Current Price | $23.17 | Mkt Cap | $7.0B |
---|---|---|---|
Open | $23.14 | P/E Ratio | 35.80 |
Prev. Close | $23.17 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $23.06 - $23.42 | Volume | 34 |
52-Wk Range | $17.90 - $24.34 | Avg. Daily Vol. | 2,310,411 |
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Current Price | $23.17 | Mkt Cap | $7.0B |
---|---|---|---|
Open | $23.14 | P/E Ratio | 35.80 |
Prev. Close | $23.17 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $23.06 - $23.42 | Volume | 34 |
52-Wk Range | $17.90 - $24.34 | Avg. Daily Vol. | 2,310,411 |
The best Bull and Bear pitches based on recency and number of recommendations.
Strong revenue growth and a oncology portfolio that is growing.
This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.
Read the most recent pitches from players about EXEL.
Recs
Strong revenue growth and a oncology portfolio that is growing.
Recs
From Fidelity or Zacks November 2021:
Revenue Growth (Last 5 Years) = 92.7%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%
Price/Sales (TTM) = 5.2
Recs
First one i picked all by myself, reason:
1. Mkt Cap 7.39B plenty place to grow
2. EPS nxt Yr 94.84%
3.EPS nxt 5Yr 46.00%
4. Sales past 5Yr 107.60%
5. Dept/ Equity 0
Issues:
1. High insider transactions almost 30%
2. Company works on cure for cancer - high volatility
3. EPS this Y -53.80% but justified by Covid-19
Practice and enjoy!
Find the members with the highest scoring picks in EXEL.
beave35 (95.23) Score: +1,535.59
The Score Leader is the player with the highest score across all their picks in EXEL.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Playa14 | < 20 |
|
5Y | $1.27 | +1,724.41% | +146.20% | +1,578.21 | 0 Comment | ||
beave35 | 95.23 | 12/23/2014 | 5Y | $1.30 | +1,682.17% | +146.58% | +1,535.59 | 0 Comment | ||
tomkao | < 20 | 12/15/2014 | 5Y | $1.40 | +1,555.00% | +154.42% | +1,400.58 | 0 Comment | ||
jack0071 | 63.23 | 12/3/2014 | 5Y | $1.43 | +1,520.28% | +147.40% | +1,372.88 | 0 Comment | ||
portefeuille | 97.18 |
|
NS | $1.44 | +1,509.03% | +153.92% | +1,355.11 | 0 Comment | ||
akoniec | < 20 | 10/9/2014 | 3Y | $1.55 | +1,394.84% | +161.22% | +1,233.62 | 0 Comment | ||
dcoyne13 | 54.35 | 9/16/2014 | 5Y | $1.62 | +1,330.16% | +156.56% | +1,173.60 | 0 Comment | ||
foolerhoff | 84.24 | 1/6/2015 | 5Y | $1.64 | +1,312.80% | +153.78% | +1,159.03 | 0 Comment | ||
garisonmp3z | < 20 | 1/5/2015 | 5Y | $1.67 | +1,287.43% | +151.19% | +1,136.23 | 0 Comment | ||
new2fool23 | 36.87 | 1/5/2015 | 1Y | $1.67 | +1,287.43% | +151.19% | +1,136.23 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.